Sanofi (SNY) Receivables (2009 - 2026)
Sanofi (SNY) posted Receivables of $10.1 billion for Q2 2026, down 63.19% sequentially from $27.5 billion in Q1 2026, and up 10.35% YoY from $9.2 billion in Q2 2025.
Sanofi (SNY) Receivables (2009 - 2026) Analysis & Trends
Sanofi has reported Receivables for 18 years, with the latest figure at $10.1 billion in Q2 2026.
- Quarterly Receivables rose 10.35% year-over-year to $10.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.1 billion (up 10.35% YoY) and the FY2025 annual result came in at $11.5 billion, up 18.09% from the prior year.
- Receivables slipped to $10.1 billion in Q2 2026 per SNY's latest filing, from $27.5 billion in the prior quarter.
- Over five years, Receivables peaked at $28.6 billion in Q3 2025 and troughed at $8.4 billion in Q4 2024.
- A 5-year average of $13.6 billion and a median of $9.4 billion in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables fell 10.07% in 2024, then grew 24.69% in 2025.
- Over 5 years, Receivables stood at $8.9 billion in 2022, then climbed by 4.59% to $9.3 billion in 2023, then dropped by 10.07% to $8.4 billion in 2024, then advanced by 24.69% to $10.5 billion in 2025, then retreated by 3.3% to $10.1 billion in 2026.
- According to Business Quant data, Receivables over the past three periods registered $10.1 billion, $27.5 billion, and $10.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.13 Bn |
| Mar 31, 2026 | 27.52 Bn |
| Dec 31, 2025 | 10.47 Bn |
| Sep 30, 2025 | 28.64 Bn |
| Jun 30, 2025 | 9.18 Bn |
| Mar 31, 2025 | 22.98 Bn |
| Dec 31, 2024 | 8.40 Bn |
| Jun 30, 2024 | 9.46 Bn |
| Dec 31, 2023 | 9.34 Bn |
| Jun 30, 2023 | 9.26 Bn |
| Dec 31, 2022 | 8.93 Bn |
| Jun 30, 2022 | 8.51 Bn |
| Dec 31, 2021 | 9.58 Bn |
| Jun 30, 2021 | 8.27 Bn |
| Dec 31, 2020 | 8.99 Bn |
| Jun 30, 2020 | 7.94 Bn |
| Dec 31, 2019 | 1.04 Bn |
| Jun 30, 2019 | 8.30 Bn |
| Dec 31, 2018 | 8.39 Bn |
| Sep 30, 2018 | 124.45 Mn |